All In Biotech

Drug Trial Radar · NCT00349375

Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy

A Multicenter, Double-Blind, Randomized, Active Comparator, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Simvastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 20 mg Simvastatin Alone

Last checked: Nov 20, 2026Latest source record: Jul 8, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,040 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,040

Actual

Start

Nov 2005

Primary completion

Sep 2008

Study completion Sep 2008

Sponsor

Lead sponsor
Solvay PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jul 7, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia. The overall objective of the study is to evaluate the efficacy and safety of combining fenofibrate and simvastatin in patients with mixed hyperlipidemia at risk of cardiovascular diseases.

Conditions

  • Hyperlipidemia

Interventions

  • Fenofibrate/SimvastatinDrug

    Combination of Fenofibrate 145mg and Simvastatin 20mg

  • Fenofibrate/SimvastatinDrug

    Combination of Fenofibrate and Simvastatin 40 mg

  • SimvastatinDrug

    Simvastatin 40 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline to 24 weeks of treatment in TriglyceridesTime frame: 12 weeks
  2. Percent change from baseline to 24 weeks of treatment in HDL-CTime frame: 12 weeks
  3. Percent change from baseline to 24 weeks of treatment in LDL-CTime frame: 12 weeks

Locations

110 sites in 8 countries. Site status is shown where the registry gives one.

  • Site 008

    Brno, Czechia

  • Site 009

    Brno, Czechia

  • Site 010

    Brno, Czechia

  • Site 015

    Hradisk, Czechia

  • Site 019

    Karlovy Vary, Czechia

  • Site 014

    Kladno, Czechia

  • Site 005

    Nymburk, Czechia

  • Site 012

    Olomouc, Czechia

  • Site 013

    Olomouc, Czechia

  • Site 007

    Pilsen, Czechia

  • Site 018

    Pilsen, Czechia

  • Site 001

    Prague, Czechia

  • Site 002

    Prague, Czechia

  • Site 003

    Prague, Czechia

  • Site 004

    Prague, Czechia

  • Site 016

    Příbram, Czechia

  • Site 017

    Příbram, Czechia

  • Site 011

    Slaný, Czechia

  • Site 006

    Tábor, Czechia

  • Site 201

    Copenhagen, Denmark

  • Site 205

    Copenhagen, Denmark

  • Site 203

    Hvidovre, Denmark

  • Site 302

    Bouliac, France

  • Site 314

    Briollay, France

  • Site 318

    Corsept, France

  • Site 301

    Dijon, France

  • Site 317

    La Montagne, France

  • Site 321

    Le Mesnil En Valee, France

  • Site 316

    Loudon, France

  • Site 308

    Mont-de-Marsan, France

  • Site 312

    Mûrs-Erigné, France

  • Site 310

    Nantes, France

  • Site 304

    Niort, France

  • Site 319

    Orvault, France

  • Site 306

    Paris, France

  • Site 305

    Pouilly-en-Auxois, France

  • Site 307

    Rouen, France

  • Site 311

    Rouen, France

  • Site 303

    Saint-Justin, France

  • Site 315

    Thouars, France

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.